Marisa R Moroney1, Kurtis D Davies2, Adam C Wilberger2, Jeanelle Sheeder3, Miriam D Post4, Amber A Berning2, Christine Fisher5, Carolyn Lefkowits6, Saketh R Guntupalli6, Kian Behbakht6, Bradley R Corr6. 1. University of Colorado Denver, Department of Obstetrics and Gynecology, Aurora, CO, United States of America. Electronic address: marisa.moroney@ucdenver.edu. 2. University of Colorado Denver Aurora, Department of Pathology, CO, United States of America. 3. University of Colorado Denver, Department of Obstetrics and Gynecology, Aurora, CO, United States of America. 4. University of Colorado Denver, Department of Obstetrics and Gynecology, Aurora, CO, United States of America; University of Colorado Denver Aurora, Department of Pathology, CO, United States of America. 5. University of Colorado Denver Aurora, Department of Radiation Oncology, CO, United States of America. 6. University of Colorado Denver Aurora, Department of Gynecologic Oncology, CO, United States of America.
Abstract
OBJECTIVES: Stage I, grade 1 endometrial cancers have low recurrence rates and often do not receive adjuvant therapy. We compared recurrent cases to matched non-recurrent controls to evaluate for molecular markers associated with higher risk of recurrence. METHODS: A case-control study including all cases of recurrent stage I, grade 1 endometrioid endometrial cancer at one institution in a ten-year period. Cases were matched to controls by age, BMI, weight and stage. Molecular testing and immunohistochemistry were performed on archival tumor specimens: microsatellite instability (MSI-H), mismatch repair status, POLE mutational status, and next-generation sequencing. RESULTS: 15 stage I, grade 1 endometrial cancer cases with recurrent disease and available tumor specimens were identified. CTNNB1 and MSI-H were present at significantly higher rates in cases than controls (CTNNB1 60% vs. 28%, OR 3.9, 95%CI 1.1-14.7, p = 0.04 and MSI-H 53% vs. 21%, OR 4.4, 95%CI 1.1-17.0, p = 0.03). POLE mutations were found in 0% of cases vs. 7% of controls (p = 0.54). Among specimens demonstrating microsatellite stability (MSS), 100% of cases vs. 26% of controls had CTNNB1 mutations (p < 0.001). CTNNB1 wild type tumors were MSI-H in 100% of cases vs. 19% of controls (p < 0.001). CONCLUSIONS: Compared to controls, CTNNB1 mutation is present at significantly higher rates in recurrent stage I, grade 1 endometrial cancers and is found most commonly in MSS tumors. MSI-H is also present at significantly higher rates in recurrent cases. These markers may be useful for prognostic risk stratification and adjuvant therapy decision-making in this otherwise low-risk population.
OBJECTIVES: Stage I, grade 1 endometrial cancers have low recurrence rates and often do not receive adjuvant therapy. We compared recurrent cases to matched non-recurrent controls to evaluate for molecular markers associated with higher risk of recurrence. METHODS: A case-control study including all cases of recurrent stage I, grade 1 endometrioid endometrial cancer at one institution in a ten-year period. Cases were matched to controls by age, BMI, weight and stage. Molecular testing and immunohistochemistry were performed on archival tumor specimens: microsatellite instability (MSI-H), mismatch repair status, POLE mutational status, and next-generation sequencing. RESULTS: 15 stage I, grade 1 endometrial cancer cases with recurrent disease and available tumor specimens were identified. CTNNB1 and MSI-H were present at significantly higher rates in cases than controls (CTNNB1 60% vs. 28%, OR 3.9, 95%CI 1.1-14.7, p = 0.04 and MSI-H 53% vs. 21%, OR 4.4, 95%CI 1.1-17.0, p = 0.03). POLE mutations were found in 0% of cases vs. 7% of controls (p = 0.54). Among specimens demonstrating microsatellite stability (MSS), 100% of cases vs. 26% of controls had CTNNB1 mutations (p < 0.001). CTNNB1 wild type tumors were MSI-H in 100% of cases vs. 19% of controls (p < 0.001). CONCLUSIONS: Compared to controls, CTNNB1 mutation is present at significantly higher rates in recurrent stage I, grade 1 endometrial cancers and is found most commonly in MSS tumors. MSI-H is also present at significantly higher rates in recurrent cases. These markers may be useful for prognostic risk stratification and adjuvant therapy decision-making in this otherwise low-risk population.
Authors: W T Creasman; F Odicino; P Maisonneuve; M A Quinn; U Beller; J L Benedet; A P M Heintz; H Y S Ngan; S Pecorelli Journal: Int J Gynaecol Obstet Date: 2006-11 Impact factor: 3.561
Authors: Aline Talhouk; Melissa K McConechy; Samuel Leung; Winnie Yang; Amy Lum; Janine Senz; Niki Boyd; Judith Pike; Michael Anglesio; Janice S Kwon; Anthony N Karnezis; David G Huntsman; C Blake Gilks; Jessica N McAlpine Journal: Cancer Date: 2017-01-06 Impact factor: 6.860
Authors: Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz Journal: N Engl J Med Date: 2015-05-30 Impact factor: 91.245
Authors: Yuexin Liu; Lalit Patel; Gordon B Mills; Karen H Lu; Anil K Sood; Li Ding; Raju Kucherlapati; Elaine R Mardis; Douglas A Levine; Ilya Shmulevich; Russell R Broaddus; Wei Zhang Journal: J Natl Cancer Inst Date: 2014-09-10 Impact factor: 13.506
Authors: A Talhouk; M K McConechy; S Leung; H H Li-Chang; J S Kwon; N Melnyk; W Yang; J Senz; N Boyd; A N Karnezis; D G Huntsman; C B Gilks; J N McAlpine Journal: Br J Cancer Date: 2015-06-30 Impact factor: 7.640
Authors: Jennifer G Haag; Rebecca J Wolsky; Marisa R Moroney; Jamie Sheren; Jeanelle Sheeder; Benjamin G Bitler; Bradley R Corr Journal: Int J Gynecol Pathol Date: 2022-03-14 Impact factor: 3.326
Authors: Marina Stasenko; Noah Feit; Simon S K Lee; Cassandra Shepherd; Robert A Soslow; Karen A Cadoo; Kaled Alektiar; Edaise M Da Silva; Ana Paula Martins Sebastião; Mario M Leitao; Ginger Gardner; Pier Selenica; Nadeem R Abu-Rustum; Britta Weigelt; Jennifer J Mueller Journal: Int J Gynecol Cancer Date: 2020-05-05 Impact factor: 3.437
Authors: Alexandra McMellen; Elizabeth R Woodruff; Bradley R Corr; Benjamin G Bitler; Marisa R Moroney Journal: Int J Mol Sci Date: 2020-06-16 Impact factor: 5.923
Authors: Diocésio Alves Pinto de Andrade; Luciane Sussuchi da Silva; Ana Carolina Laus; Marcos Alves de Lima; Gustavo Nóriz Berardinelli; Vinicius Duval da Silva; Graziela de Macedo Matsushita; Murilo Bonatelli; Aline Larissa Virginio da Silva; Adriane Feijó Evangelista; Jesus Paula Carvalho; Rui Manuel Reis; Ricardo Dos Reis Journal: Front Oncol Date: 2021-08-17 Impact factor: 6.244